{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:01:48Z","timestamp":1791514908896,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00259-023-06340-y","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T05:01:43Z","timestamp":1689656503000},"page":"3777-3789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study"],"prefix":"10.1007","volume":"50","author":[{"given":"Sanjana","family":"Ballal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav P","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhana","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant A","family":"Damle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit K","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-5584","authenticated-orcid":false,"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"6340_CR1","doi-asserted-by":"publisher","unstructured":"Alam MR, Singh SB, Thapaliya S, et al. A Review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging theranostic agents in prostate cancer. Cureus 2022;14(9):e29369.\u00a0https:\/\/doi.org\/10.7759\/cureus.29369.","DOI":"10.7759\/cureus.29369"},{"key":"6340_CR2","doi-asserted-by":"crossref","unstructured":"Labriola MK, Atiq S, Hirshman N, Bitting RL. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis. 2021;24:301\u20139.","DOI":"10.1038\/s41391-020-00299-9"},{"key":"6340_CR3","doi-asserted-by":"crossref","unstructured":"Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020;30:98\u2013105.","DOI":"10.1097\/MOU.0000000000000685"},{"key":"6340_CR4","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u20131103.","DOI":"10.1056\/NEJMoa2107322"},{"key":"6340_CR5","doi-asserted-by":"crossref","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Am J Roentgenol. 2019;213:275\u201385.","DOI":"10.2214\/AJR.18.20845"},{"key":"6340_CR6","doi-asserted-by":"crossref","unstructured":"Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J. Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? EJNMMI Res. 2022;12:20.","DOI":"10.1186\/s13550-022-00891-1"},{"key":"6340_CR7","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225 Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57:1941\u201344.","DOI":"10.2967\/jnumed.116.178673"},{"key":"6340_CR8","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted \u03b1-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225 Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624\u201331.","DOI":"10.2967\/jnumed.117.191395"},{"key":"6340_CR9","doi-asserted-by":"crossref","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129\u201338.","DOI":"10.1007\/s00259-018-4167-0"},{"key":"6340_CR10","doi-asserted-by":"crossref","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225 Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients. Theranostics. 2020;10:9364\u201377.","DOI":"10.7150\/thno.48107"},{"key":"6340_CR11","doi-asserted-by":"crossref","unstructured":"Ma J, Li L, Liao T, Gong W, Zhang C. Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:796657.","DOI":"10.3389\/fonc.2022.796657"},{"key":"6340_CR12","doi-asserted-by":"crossref","unstructured":"Lee DY, Kim Y il. Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. J Nucl Med. 2022;63:840\u2013846.","DOI":"10.2967\/jnumed.121.262017"},{"key":"6340_CR13","doi-asserted-by":"crossref","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, et al. mCRPC Patients Receiving 225 Ac-PSMA-617 Therapy in the Post\u2013Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J Nucl Med. 2022;63:1496\u20131502.","DOI":"10.2967\/jnumed.121.263618"},{"key":"6340_CR14","doi-asserted-by":"crossref","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. J Nucl Med. 2020;61:62\u201369.","DOI":"10.2967\/jnumed.119.229229"},{"key":"6340_CR15","doi-asserted-by":"crossref","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration -Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318.","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"6340_CR16","unstructured":"Goldmacher G. (n.d.) Imaging Response Criteria Training for PCWG-Modified RECIST 1.1. Published by Articulate\u00ae Storyline. https:\/\/www.articulate.com. Accessed 24 July 2022."},{"key":"6340_CR17","unstructured":"McCaffery M &Pasero C. Pain: Clinical Manual. 2nd ed. St Louis, MO: Mosby; 1999."},{"key":"6340_CR18","doi-asserted-by":"crossref","unstructured":"Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:139 \u201344.","DOI":"10.1093\/geronj\/46.4.M139"},{"key":"6340_CR19","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Publish Date: November 27, 2017."},{"key":"6340_CR20","doi-asserted-by":"crossref","unstructured":"Ballal S, Yadav MP, Sahoo RK, Tripathi M, Dwivedi SN, Bal C. 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Prostate. 2021;81:580\u201391.","DOI":"10.1002\/pros.24137"},{"key":"6340_CR21","doi-asserted-by":"crossref","unstructured":"Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"6340_CR22","doi-asserted-by":"crossref","unstructured":"Rathke, H., Kratochwil, C., Hohenberger, R. et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46:139\u201347.","DOI":"10.1007\/s00259-018-4135-8"},{"key":"6340_CR23","doi-asserted-by":"crossref","unstructured":"Feuerecker B, Tauber R, Knorr K, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350.","DOI":"10.1016\/j.eururo.2020.11.013"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06340-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:08:07Z","timestamp":1696324087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6340"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06340-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"23 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors have no conflict of interest","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical clearance received Ref. No IEC-518\/2018, RP-18\/2018.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Clearance"}},{"value":"Written informed consent was obtained from all patients to participate in the study and for the use of clinical information to analyze data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The Indian Council of Medical Research, under project No. 3\/2\/3\/96\/2019\/NCD-III, provided funding support for a portion of the manpower involved in this work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Support"}},{"value":"This work has not been submitted elsewhere as a full article and is not under consideration by any other journal.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}